Pain can be defined as an
unpleasant sensation that is transferred by the sensory neurons to the brain. The adversity of pain is
not limited to physical sensations. According to International Association for the Study
of Pain (IASP), it is a distressing sensory and emotional experience
combined with potential tissue damage. There are four major types of pain, the one caused by nerve irritation
known as neuropathic pain, the one that typically arises as the result of
tissue injury known as nociceptive pain, the abnormal inflammation arises due
to improper response by the immune system of the body known as inflammatory
pain and lastly, functional pain which has no obvious origin. Pain is one of the
major issues which deteriorates the health and as per studies and estimations 1
in every 5 adults suffer from pain. Moreover, it has been found that globally, 1 in 10 adults are
diagnosed with chronic pain each year.
The pain can be experienced in any form,
chronic, acute or intermittent. There are numerous causes of pain with cancer,
post-operative pain, migraine, arthritis, post-operation and injuries being the
major ones. According to a research study conducted in 2019, in the UK alone
13–50% of adults are already affected by chronic pain.
Pain management is an interdisciplinary
approach which evaluates the pain, ease the suffering caused by the pain and
improves the quality of life and health. The aid approach of pain management
ranges from sudden pain issues such as headaches to many types of long-lasting
pain such as low back pain. Pain management uses a range of medication to reduce or treat the pain and
there are many underlying physiological mechanisms behind this. The medications
may target nociceptors or prevents the injured or damaged cells from producing
and releasing prostaglandin.
Market Insights
Pain management drugs performs actions in numerous ways to prevent, reduce,
or stop pain sensations. According to Report Ocean study, the Global Pain Management Drugs market was approximately US$
65,963.1 million in
2019 and is anticipated to reach $85,549.3 million by 2027 growing at a rate of 3.9% over the forecast
period 2020-2027.
This report forecasts growth of Pain Management Drugs market
at
global level and provides an insight of the latest trends. For the current
analysis, Report Ocean has segmented the market by drug class, by indication
and by region.
·
Drug class
v
NS AIDs (Non-Steroidal Anti-Inflammatory
Drugs)
v Anesthetics Antidepressants
v
Anticonvulsants
v
Anti-migraine Agents
v
Antidepressants
v
Opoids
·
Indication
v Arthritic Pain
v Neuropathic Pain
v Cancer Pain
v Chronic Back Pain
v Postoperative Pain
v Migraine
v Fibromyalgia
·
Region
v North America
v Europe
v Asia Pacific
v LAMEA
Rise in geriatric population is the main
factor that drives growth of the global pain management market, as this
population pool often suffers from joint pain and other chronic conditions.
Moreover, rise in prevalence of chronic diseases, such as cancer, diabetic
neuropathy, and osteoarthritis further increases the market growth. As per the
National Cancer Institute, almost 50% of cancer patients undergo moderate to
severe pain. Furthermore, increasing surgical processes and rise in healthcare
expenditure fuelled growth of the market. Contrary to this, drug exploitation,
patent expiration of prescription pain medication drugs, and availability of
substitutes restrains the market growth.
The largest contributor to the market in 2019 was
opioids segment, due to rising prevalence of chronic conditions and high
efficiency of opioids to relieve pain under these conditions. The anesthetics
segment is expected to possess highest growth rate during the forecast period
2020-2027. By indication, the neuropathic pain segment accounted for largest
market share in 2019 owing to presence of large patient population that
increases demand for drugs and is expected to maintain that position in the
forecast period. Cancer pain and chronic back pain segments are also expecting
growth owing to rise in surgeries at global level and elevating prevalence of
back pain causing chronic diseases.
Among the key regions taken into
consideration for the study and analysis of the global pain management drug market,
the leading country with large pool of aging population and well-regulated
conditions was North America in 2019. However, due to elevated cases of drug
abuse and addictive nature of opioids,
the use of prescribed opioids has been decreased, leading to decline in opioid
consumption for pain management. While, Asia-Pacific with larger patient pool and increased healthcare
expenditure is anticipated to experience highest growth rate during the
forecast period.
Major market players of Global
Pain Management Drugs included in this report are the following:
·
Abbott Laboratories
·
Eli Lilly & Company
·
Neurocrine Biosciences
·
GlaxoSmithKline Plc.
·
Johnson & Johnson
·
Merck & Co. Inc.
·
Mylan NV.
·
Novartis AG
·
Pfizer, Inc.
·
Purdue Pharma L.P.
·
Allergen Inc.
·
Bayer AG
·
Bristol-Myers Squibb
Marketed Products
Anjeso, meloxicam injection
developed by Baudax Bio has been approved by the FDA in February, 2020
for the management of moderate to severe pain, alone or in combination with
other non-NSAID analgesics. It will be administered once-a-day through
intravenous (IV) route. The active ingredient meloxicam possesses analgesic,
anti-inflammatory and antipyretic activities that inhibit the cyclooxygenase
type 2 pathway (COX-2), and subsequently reduces prostaglandin biosynthesis.
Emgality injection, developed by Eli
Lilly and Company was initially approved in 2018 to prevent migraine, later
in 2019 the same injection received further approval by the FDA for the
treatment of episodic cluster headache in adults. It is the first FDA-approved
drug that reduces the frequency of attacks of episodic cluster headache. These
attacks may strike several times a day, lasting between 15 minutes and three
hours.
Orilissa (elagolix), an oral treatment for the management of moderate to severe pain
associated with endometriosis developed by Neurocrine Biosciences was
approved by the FDA in August, 2018. Endometriosis is a common condition that
affects approximately one in 10 women of reproductive age.
Exparel (bupivacaine liposome injectable suspension), developed by Pacira Pharmaceuticals, Inc. was initially approved in 2011 as a single use injection into a surgical site to produce post-surgery pain relief. However, in 2018 it was approved by the FDA to be used as a nerve block to help adult patients with pain management for 48 hours after shoulder surgery.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:
https://www.reportocean.com/industry-verticals/sample-request?report_id=AMR1172